<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1052243361488264&amp;ev=PageView&amp;noscript=1">

This breakthrough multiplexed assay supports the simultaneous detection of antibodies targeting multiple SARS-CoV-2 antigens.

The FlowMetric multiplex serology assay provides double the amount of information over the same testing time period compared to other existing assays run on ELISA and lateral flow platforms.

For vaccine development efforts, the novel FlowMetric assay can differentiate a clinical infection from a vaccine response. People immunized with the Spike(S) or Receptor-Binding Domain (RBD) protein will be positive for that antigen but negative on the Nucleocapsid (N) antigen, while those exposed to the actual virus will be positive on both.

If you would like to learn more about FlowMetric’s novel serology assay, please complete the form below and we will get back to you within 24 hours.

FlowMetric’s novel SARS-CoV-2 serology assay delivers:

Detects antibodies targeting multiple viral antigens


of clinical infection from a vaccine response


range of antibody detection

The FlowMetric Advantage

The applications of this breakthrough multiplexed assay are ideal for companies working on vaccine development or looking to identify modulation of SARS-CoV-2 antibodies in the development of therapeutic modalities.